Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
17 hedge funds and large institutions have $1.62M invested in Avenue Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 11 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
29% less funds holding
Funds holding: 24 → 17 (-7)
44% less capital invested
Capital invested by funds: $2.88M → $1.62M (-$1.26M)
64% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$88.9K |
| 2 |
Renaissance Technologies
New York
|
+$72.3K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$49.6K |
| 4 |
KAS
Kestra Advisory Services
Austin,
Texas
|
+$41.3K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$10.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$88K |
| 2 |
E
Ergoteles
New York
|
-$76K |
| 3 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$68.2K |
| 4 |
VF
Virtu Financial
New York
|
-$66K |
| 5 |
Goldman Sachs
New York
|
-$58K |
ATXI Hedge Fund Activity: Q3 2021 in Review
17 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q3 2021, worth a combined $1.62M — down 44% from $2.88M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ATXI and 4 opened new positions — a net loss of 7 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was Wells Fargo, opening a new position worth an estimated $88.9K. The largest seller was Advisory Services Network, exiting entirely with an estimated $88K sold.
- 17 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q3 2021, down from 24 in Q2 2021.
- Funds reported $1.62M of Avenue Therapeutics, Inc. Common Stock stock for Q3 2021, down 44% quarter-over-quarter.
- 4 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q3 2021 and 11 closed out, a net change of -7 holders.
- The largest Avenue Therapeutics, Inc. Common Stock buyer in Q3 2021 was Wells Fargo, an estimated $88.9K added.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q3 2021 was Advisory Services Network, an estimated $88K sold.
Based on aggregated 13F filings for Q3 2021.